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Summary 
Mitochondrial DNA (mtDNA) mutations frequently cause neurological diseases. Modeling of 
these defects has been difficult because of the challenges associated with engineering 
mtDNA. We show here that neural progenitor cells (NPCs) derived from human induced 
pluripotent stem cells (iPSCs) retain the parental mtDNA profile and exhibit a metabolic 
switch towards oxidative phosphorylation. NPCs derived in this way from patients carrying a 
deleterious homoplasmic mutation in the mitochondrial gene MT-ATP6 (m.9185T>C) showed 
defective ATP production and abnormally high mitochondrial membrane potential (MMP), 
plus altered calcium homeostasis, which represents a potential cause of neural impairment. 
High-content screening of FDA-approved drugs using the MMP phenotype highlighted 
avanafil, which we found was able to partially rescue the calcium defect in patient NPCs and 
differentiated neurons. Overall, our results show that iPSC-derived NPCs provide an effective 
model for drug screening to target mtDNA disorders that affect the nervous system. 
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Introduction 
Approximately 1 in 5,000 individuals (Gorman et al., 2015) suffer from deleterious 
mitochondrial DNA (mtDNA) mutations that can cause metabolic disorders and typically lead 
to dysfunctions of the nervous system (Carelli and Chan, 2014). Recent breakthroughs in the 
field of "mitochondrial medicine" might yield methods to prevent the transmission of 
pathogenic mtDNA mutations in the future (Mitalipov and Wolf, 2014; Reddy et al., 2015). 
But currently no cures or effective interventional therapies are available for patients who have 
already inherited the mutations and are subject to such disorders (Pfeffer et al., 2013). 
The development of new treatment options has been hampered by a lack of relevant 
models for mtDNA-related diseases, largely due to the challenges of engineering mtDNA. 
mtDNA mutations can be introduced into mouse germ cells (Inoue et al., 2000) or can be 
induced to occur as a consequence of a proof-reading deficient DNA polymerase gamma 
(Kauppila et al., 2016). However, the generated mouse models cannot recapitulate the 
heteroplasmy or tissue-specificity of mtDNA disorders. The most important cellular models 
of mtDNA diseases are based on cytoplasmic hybrids (cybrids), obtained by fusing 
immortalized human cell lines depleted of mtDNA with patient-derived enucleated cells. 
These models have permitted the identification of some of the cellular and molecular 
consequences that follow from mutations in mtDNA (King and Attardi, 1989). But cybrids 
cannot address effects that result from the interplay between mitochondrial DNA and specific 
characteristics of an individual patient's nuclear DNA, which have been shown to influence 
the course of these diseases (Benit et al., 2010; D'Aurelio et al., 2010). Additionally, the 
bioenergetics of cybrids depend on glycolysis, whereas the neuronal cells that are 
symptomatic rely on mitochondrial oxidative phosphorylation (OXPHOS) (Abramov et al., 
2010; Carelli and Chan, 2014). These significant differences limit the extent to which cybrids 
can be used as models in searching for new types of therapies.  
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Here we suggest an innovative, more potent alternative in the form of neural 
progenitor cells (NPCs), which have the characteristics needed in a model to study 
neurological diseases caused by mtDNA mutations and setting up drug discovery pipelines to 
treat them. NPCs can be rapidly obtained from induced pluripotent stem cells (iPSCs), either 
through an intermediate generation of rosettes (Koch et al., 2009) or the direct application of a 
cocktail of small molecules (Li et al., 2011; Reinhardt et al., 2013). We have previously 
shown that mitochondria undergo morphological and metabolic reconfigurations upon the 
generation of iPSCs (Prigione et al., 2010). Here we further demonstrate that when iPSCs are 
put through the steps of neural induction to become NPCs, their mitochondria undergo 
maturation and a metabolic shift towards neuronal-like oxidative metabolism, while entirely 
retaining the mitochondrial genome of the parent cell from which they were originally 
derived. 
To examine whether NPCs represent a valid cellular system for compound screening 
approaches for mtDNA diseases, we generated iPSC-derived NPCs from three patients 
carrying the mutation m.9185T>C in the MT-ATP6 gene for ATP synthase (Complex V) in a 
homoplasmic state (i.e. affecting all mtDNA molecules). This mutation is a recurrent cause of 
neurological diseases such as Leigh syndrome (Moslemi et al., 2005), NARP (Neuropathy, 
Ataxia, Retinitis Pigmentosa) (Childs et al., 2007), and episodic paralysis with spinal 
neuropathy (Aure et al., 2013). Patient-derived NPCs exhibited functional alterations 
including decreases in ATP production, abnormally increased mitochondrial membrane 
potential (MMP), and altered calcium homeostasis. We developed a high-content screening 
(HCS) strategy based on the patient MMP phenotype and used it to screen a library of FDA-
approved compounds. The phosphodiesterase type 5 (PDE5) inhibitor avanafil, a compound 
that reduced the mitochondrial hyperpolarization, also partially rescued the calcium defect in 
both patient NPCs and differentiated neurons. These findings suggest that iPSC-derived NPCs 
can be used as an innovative model system to analyze mechanisms underlying mtDNA-
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related neurological disorders and to carry out personalized phenotypic drug discovery for 
diseases that have been untreatable until now. 
 
Results 
Functional assessments of neural-induced neural progenitor cells (NI NPCs) 
A small molecule-based protocol (Li et al., 2011) was used to facilitate neural 
induction (NI) of human pluripotent stem cells (PSCs), bypassing rosette derivation (Koch et 
al., 2009), which is time-consuming and operator-dependent (Fig. S1A). Neural-induced 
neural progenitor cells (NI NPCs) were obtained from the human embryonic stem cell (hESC) 
lines H1 and H9, control iPSCs derived via transfection (TF) of episomal vectors, and control 
iPSC lines previously generated via retroviral transduction (TD) (Prigione et al., 2010; 
Prigione et al., 2011a; Prigione et al., 2011b) (Fig. S1B-H). NI NPCs grew as a uniform 
monolayer, expressed NPC marker proteins, retained their multipotent identity for over 30 
passages, and were capable of generating neuronal and glial subtypes including GABAergic 
neurons, dopaminergic neurons, and astrocytes (Fig. 1A).  
NI NPCs functionally responded to calcium mobilization, following voltage-
dependent (high potassium chloride) and receptor-dependent (glutamate) stimuli (Fig. 1B-E; 
Video S1). This led to the influx of calcium into the cells and subsequent calcium-induced 
calcium release from intracellular stores. In contrast, no response was provoked in either 
iPSCs or hESCs (Fig. 1B-E). This suggested that NI NPCs might be suitable models for an 
investigation of calcium-regulated mechanisms. Whole cell patch clamp recordings in the 
current clamp mode were performed on NI NPCs and neurons at various time points of 
differentiation. In maturing neuronal-like cells, single and repetitive action potentials 
appeared after 8-12 weeks of differentiation (Fig. S1I-J). Depolarizing currents failed to 
induce a firing of action potentials in NI NPCs (Fig. 1F). Membrane potentials and resistance, 
on the other hand, did not change significantly upon differentiation (Fig. 1G). This indicated 
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that although NI NPCs do not fire action potentials upon depolarization, their passive 
electrical properties are close to those of differentiated neuronal-like cells. 
Principal component analysis (PCA) demonstrated that the transcriptome of NI NPCs 
was similar to that of NPCs generated using the traditional rosette-based approach (rNPCs) or 
obtained from ex vivo adult human brain (eNPCs) (Fig. 1H; Fig S2A). This was also 
confirmed by comparing our data with previously published NPC transcriptomes (Brennand et 
al., 2011; Hargus et al., 2014; Li et al., 2011; Reinhardt et al., 2013; Stein et al., 2014) (Fig. 
S2B). A pathway analysis of the uniquely expressed genes in NI NPCs, rNPCs, and eNPCs 
revealed that eNPCs exhibited a higher commitment towards neuronal development compared 
to the other PSC-derived NPCs (Fig. S2C-D; Table S1). Nonetheless, NI NPCs, rNPCs, and 
eNPCs displayed a highly comparable pattern once mapped onto the human brain atlas (Fig. 
1I). Hence, PSC-derived NPCs may sufficiently represent NPCs that reside in the adult 
human brain. 
 
NI NPCs exhibit mitochondrial maturation and neuronal-like energy metabolism 
The generation of iPSCs is accompanied by an extensive restructuring of mitochondria 
and energy metabolism (Folmes et al., 2011; Prigione et al., 2010). A hierarchical clustering 
of genes involved in energy metabolism (Prigione et al., 2011b) identified differences in the 
metabolic regulation of PSCs and NPCs (including NI NPCs, rNPCs, and eNPCs) (Fig. 
1J). Clustering the samples according to OXPHOS genes produced the same pattern (data not 
shown). This suggests that NPCs may regulate cellular bioenergetics fundamentally 
differently from PSCs, irrespective of the mode by which they were derived. qPCR data 
confirmed that glycolytic regulators such as GLUT3 and PDK1- were down-regulated in 
NPCs and neurons in comparison to PSCs, indicating that neural induction is accompanied by 
a reduction of glycolytic metabolism (Fig. 1K).  
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Transmission electron microscopy showed that the mitochondria of NI NPCs display a 
fused ultrastructural morphology with well-developed cristae, resembling those of neurons but 
differing from the ultrastructure of PSC mitochondria. (Fig. 2A). In accordance, there was a 
significant increase in mitochondrial length during neural induction (Fig. 2B). 
We used seahorse technology, which concomitantly measures respiration (oxygen 
consumption rate, OCR) and glycolysis (extracellular acidification rate, ECAR), to compare 
the bioenergetic profiles of NI NPCs and neurons to those of PSCs and fibroblasts (Fig. 2C-
D). The rates of basal and maximal respiration and proton leak were similar in all cell types 
except fibroblasts, whose maximal respiration was higher (Fig. S2E-G). Fibroblasts also had 
a much higher spare respiratory capacity than NI NPCs and neurons, in which the levels were 
only slightly higher than those of PSCs (Fig. 2E). Conversely, NI NPCs and neurons 
experienced a sharp reduction in basal glycolysis compared to PSCs. This reduction was 
highly significant and more pronounced than that seen in fibroblasts (Fig. 2F). This seems to 
indicate that neural induction is associated with a strong decrease of glycolytic metabolism. 
Accordingly, the OCR/ECAR ratio increased to a similar degree in fibroblasts, NI NPCs, and 
neurons compared to PSCs, suggesting a predominance of OXPHOS over glycolysis in these 
cell types (Fig. 2G). This finding was supported by the lower amounts of extracellular lactate 
found in NI NPCs and neurons than in PSCs (Fig. 2H). The fact that NI NPCs could be 
maintained in glucose-free galactose medium, which requires using OXPHOS (Fig 2I), is 
further evidence of a lower dependence on glycolysis.  
These data suggest that neural induction triggers mitochondrial maturation, leading to 
an oxidative metabolic state in NI NPCs which resembles that of neurons.  
  
NI NPCs retain their parental mtDNA sequence profile 
To make useful models of mitochondrial diseases from NI NPCs, we needed to 
exclude the possibility that mtDNA had undergone changes during stages of induction, as can 
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happen in the generation of iPSCs (Ma et al., 2015; Prigione et al., 2011b). We performed 
Sanger sequencing of the entire mtDNA, using long-range PCR with nested primers to 
exclude nuclear mtDNA pseudogenes. We analyzed BJ control fibroblasts, BJ-derived TD-
iPSCs, BJ-derived TF-iPSCs, hESCs, and the NI NPCs generated from the PSCs.  
We found that the specific mtDNA variants from each individual were fully retained 
upon iPSC derivation, regardless of the reprogramming method that was used. This was also 
true upon neural induction (Fig. 3A, Table S2), irrespective of the type of variant and its 
location within the mtDNA sequence (Fig. 3B). Remarkably, even the spectrum of D310 tract 
heteroplasmy in the hypervariable region of the D-loop (mtDNA nt 57-372) was preserved 
through these stages (Fig. 3C) (its high heterogeneity makes it a common tool for forensic 
fingerprinting).  
Finally, in contrast to a recent report on hESCs (Van Haute et al., 2013), we used two 
distinct long-range PCR protocols to dismiss the possibility that large mtDNA deletions had 
occurred in PSCs (including hESCs, TD-iPSCs and TF-iPSCs) or NI NPCs (Fig. 3D). These 
results demonstrate that NI NPCs can maintain the mtDNA profile of the primary cells from 
which they are derived.  
 
Generation of patient NI NPCs carrying a homoplasmic MT-ATP6 mutation 
NI NPCs may represent a bona fide model system for mtDNA-related neurological 
diseases because they share features with brain-derived neural cells (Fig. 1I), rely on 
mitochondrial metabolism (Fig. 2A-I), and retain the parental mtDNA profile (Fig. 3A-D). To 
replicate these findings in a real-case scenario, we derived NI NPCs from three patients from 
a family that harbors the homoplasmic mutation m.9185T>C in the MT-ATP6 gene (Aure et 
al., 2013) (Fig. S3A-F). The cells, to which we assigned the common designation 
NPC_ATP6, comprised NI A1 (from the iPSC line TFA1), NI A2 (iPSC line TDA2.3), and 
NI A3 (iPSC line TDA3.1) and expressed the correct NPC protein markers (Fig. 4A).  
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We used whole mtDNA sequencing and RFLP analysis to demonstrate that 
NPC_ATP6 retained the mtDNA of the original fibroblasts. The cells exhibited homoplasmic 
levels of the m.9185T>C mutation without any additional mtDNA mutations (Fig. 4B-C; Fig. 
S4A-C). NPC_ATP6 also maintained intact versions of the parental D310 hypervariable 
regions of the D-loop and did not undergo any mtDNA deletions (Fig. S4D-F). This means 
that any cellular phenotypes in NPC_ATP6 that are driven by the mitochondrial genome can 
be solely attributed to the patient-specific MT-ATP6 mutation. 
 
Bioenergetic consequences of the homoplasmic MT-ATP6 mutation 
Direct measurements of ATP production in permeabilized NPC_ATP6 cells revealed a 
significant defect (Fig. 4D) similar to that found in the primary fibroblasts from which they 
were obtained (Fib_ATP6) and in three independent cybrid clones derived from A1 
fibroblasts (Cyb_ATP6) (Fig. 4D). In spite of this, we found unaffected steady-state levels of 
ATP in intact NPC_ATP6, whether grown under standard conditions or after 4 hours in 
starvation medium, and in Fib_ATP6 and Cyb_ATP6 (Fig. 4E). Accordingly, the reduced 
production of ATP in NPC_ATP6 did not affect the cells' metabolic profile under basal or 
starvation states as assessed with Seahorse technology (Fig. S5A-D) or their extracellular 
lactate content (Fig S5E). This suggests that cells carrying the m.9185T>C mutation had 
efficiently adapted their energy expenditure to the lower levels of ATP. This behavior is also 
encountered in physiological conditions when there is an energy shortage (Staples and Buck, 
2009), and is also in agreement with clinical observations (Campbell and Marcinek, 2016). 
One of the adjustments probably involves the partial depolarization of the plasma membrane 
(Aure et al., 2013), as we observed in NPC_ATP6 using electrophysiology analysis (Fig. 4F).  
The proliferation rates of NPC_ATP6, Fib_ATP6, and Cyb_ATP6 were likewise 
unaffected in glucose medium or during the shift of cellular metabolism towards OXPHOS in 
galactose medium (Fig. 4G). NPC_ATP6 appeared to have normal mtDNA copy number, 
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(Fig. S5F) and mitochondrial ultrastructure and distribution (Fig. S5G-H). Measurements of 
the kinetics of MitoSox signal revealed no change in the production of superoxide ions in 
NPC_ATP6 and Cyb_ATP6, in contrast to significant increases that have been previously 
observed in Fib_ATP6 (Fig. 4H) (Aure et al., 2013). These findings suggest that distinct cell 
types find different ways of responding to the same bioenergetic challenge. So in seeking the 
mechanisms responsible for the neural impairment associated with MT-ATP6 mtDNA 
mutations, neural-like cells should be used (Abramov et al., 2010). 
 
Mitochondrial hyperpolarization in neural cells carrying the MT-ATP6 mutation 
We next used a permeabilization-based method to measure the mitochondrial 
membrane potential (MMP) of NPC_ATP6, Fib_ATP6, and Cyb_ATP6. We observed an 
increase of MMP, as expected, in the presence of ADP, which is the substrate of ATP 
synthase that induces state 3 respiration (Fig. S6A-C). Treating all permeabilized cells with 
oligomycin, an inhibitor of ATP synthase that induces state 4 respiration, revealed normal 
MMP (Fig. S6A-C). Importantly, between state 3 and 4 respiration, individual NPC_ATP6 
cells experienced a sharp decrease in MMP. (Fig. 5A). The significance of the change was 
lower in mutant cybrids, and did not reach significance in patient fibroblasts (Fig. 5A). This 
suggested that NPCs might not regulate MMP as efficiently as either fibroblasts or cybrids. 
Next we carried out an imaging-based assessment of MMP in live, intact cells. This 
revealed a significant, abnormal increase in MMP in NPC_ATP6 cells, but not in Fib_ATP6 
or Cyb_ATP6 (Fig. 5B). To control for technical bias, we demonstrated that oligomycin 
induced similar increases in the MMP signal in the three cell types (Fig. S6D). Notably, 
neurons derived from patient NPCs (Neur_ATP6) also exhibited mitochondrial 
hyperpolarization (Fig. 5C). We could exclude differentiation defects as the cause, since 
populations of Neur_ATP6 and control neurons (Neur_Ctrl) had a similar number of TUJ1-
positive cells. (Fig. 5D; Fig S6E). Furthermore, the mitochondria of Neur_ATP6 had normal 
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morphology and lengths compared to Neur_Ctrl (Fig. 5E-F). This means that the phenotypes 
observed in differentiated neurons replicated those observed in NI NPCs, including the 
abnormal MMP increase.  
MT-ATP6 mutation may thus specifically disrupt the ability of neural cells (including 
neural progenitor cells and post-mitotic neurons) to control MMP under basal conditions, an 
effect that is not seen in cybrids or fibroblasts. 
 
Altered mitochondrial calcium homeostasis in NPC_ATP6 
To gain further insights into the pathophysiology of the MT-ATP6 mutation, we 
interrogated the global transcriptome of control and patient NPCs (Table S1). We found a 
variable modulation of the expression of genes encoding for mitochondrial complexes, which 
supported our bioenergetic findings and excluded a uniform functional transcriptional 
compensatory response in NPC_ATP6 (Fig S6F). On the other hand, genes involved in 
mitochondrial calcium homeostasis were consistently down-regulated in NPC_ATP6 (Fig. 
S6G). A cluster analysis of these genes permitted us to observe patterns that clearly 
distinguished patient-derived NI NPCs from control NI NPCs. In particular, NPC_ATP6 
showed significant down-regulation of LETM1 in the inner mitochondrial membrane, VDAC3 
in the outer mitochondrial membrane, and ATP5O, which encodes for oligomycin sensitivity-
conferring protein (OSCP) whose decreased expression is associated with enhanced 
sensitivity of the permeability transition pore (PTP) to calcium (Giorgio et al., 2013) (Fig. 
6B). These disease-specific patterns were not found in PSCs or fibroblasts, which makes 
sense because those cells do not develop symptoms in the diseases (Fig. 6A). 
A global proteomics analysis confirmed that calcium homeostasis was likely being 
altered in NPC_ATP6s. A pair-wise analysis revealed a down-regulation of components of the 
“calcium signaling” pathway in all three patient NPC lines compared to control lines (Fig. 
6C). Additional pathways that were down-regulated in NPC_ATP6s related to the 
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“mitochondrial membrane” and “electron carrier activity” (Fig. S6H), while the “apoptosis” 
and “p53/hypoxia" pathways were up-regulated compared to controls (Fig. S6I).  
Given the coherent picture of calcium dyshomeostasis from the "-omics" analyses, we 
set up calcium imaging experiments to pursue its functional relevance. Stimulating 
NPC_ATP6 cells with glutamate led to decreased calcium-induced calcium release from 
intracellular stores (Fig. 6D; Video S2). To avoid effects dependent on the plasma membrane, 
which was partially depolarized in the patient cells (Fig. 4F), we analyzed calcium 
homeostasis in permeabilized NI NPCs exposed to increasing doses of external calcium. 
NPC_ATP6 displayed a significant reduction in the acute increase of Fluo-4-labeled cytosolic 
calcium which occurred after the third calcium addition (Fig. 6E). This was also the case 
following treatment with a combination of FCCP and antimycin A, which depolarizes the 
MMP leading to the release of mitochondrial calcium into the cytosol (Fig. 6F). In contrast, 
treatment with thapsigargin, which blocks calcium uptake resulting into calcium release from 
the endoplasmic reticulum, induced a similar cytosolic calcium increase in both patient and 
control NPCs (Fig. 6G).  
Defects in the handling of calcium impair cellular functions, particularly in neuronal 
cells (Neher and Sakaba, 2008), which may help explain why symptoms arise specifically in 
the neurons of patients with ubiquitous MT-ATP6 homoplasmic mutations. Moreover, the 
findings pointed to a specific alteration in mitochondrial calcium homeostasis, which is 
strongly influenced by the state of mitochondrial polarization (Rizzuto et al., 2012). This fits 
with our finding that Cyb_ATP6 achieves better MMP regulation (Fig. 5A-B) and exhibits 
normal calcium responses (Fig. 6H-I).  
 
Phenotypic compound screenings in NPC_ATP6 
We next sought to address whether NPCs might be suitable for drug discovery 
approaches, targeting the aberrant MMP phenotype identified in patient NPCs and confirmed 
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in patient neurons. We adapted the imaging-based MMP assay to a 384-well plate format that 
could be used with the high-content screening (HCS) automated fluorescence microscope 
Cellomics ArrayScan (Fig. 7A). As a proof-of-concept, we tested 130 compounds from a 
library of 700 FDA-approved drugs (Table S3) for effects on the cells' MMP. In order to 
overcome a degree of variability inherent to the assay, we used each compound in duplicate 
and repeated the same screening twice. To reduce the risk of false negatives, we focused on 
NI A2, the NPC_ATP6 line with the highest MMP. Each compound was used at a final 
concentration of 1 µM and was dissolved in 0.04% DMSO, a dose that we verified as non-
toxic and with no direct influence on the MMP (Fig. S7A-B). Ten compounds decreased the 
MMP of NI A2 down to -2 standard deviation values (Fig. 7B) without negatively affecting 
the cells' viability (Fig. S7C-D).  
We decided to focus on one of these compounds: avanafil (Fig. 7B), a 
phosphodiesterase type 5 (PDE5) inhibitor. The family of compounds to which this belongs is 
commonly used against erectile dysfunction in adults and is approved for pediatric use to treat 
pulmonary arterial hypertension (Archer and Michelakis, 2009). These compounds can cross 
the blood brain barrier and have been reported to have positive effects on neurogenesis 
(Garcia-Barroso et al., 2013; Rutten et al., 2008). We assessed avanafil's impact on 
bioenergetics and calcium homeostasis in patient-derived NPCs and differentiated neurons. 
Treatment with 1 µM avanafil overnight induced a slight but significant depolarization of 
mitochondria, similar to that seen in state 3 and state 4 respiration (Fig. S7E-F). Despite this 
partial depolarization, there was no significant change in the rate of ATP production in 
NPC_ATP6 (Fig. 7C). The ATP steady-state level remained constant also in patient neurons 
after exposure to the drug (Fig. 7D).  
Avanafil did not alter the profile of cytosolic calcium in NPC_ATP6 when increasing 
doses of external calcium were applied (Fig. 7E-F). Importantly, however, the overnight 
treatment with avanafil increased the release of mitochondrial calcium when we triggered 
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mitochondrial depolarization using FCCP and antimycin A in the three NPC_ATP6 lines, 
reaching significance in two of them (Fig. 7G-H). Avanil also induced a similar increase in 
mitochondrial calcium release in differentiated neurons carrying the MT-ATP6 mutation (Fig. 
7I-J). 
Overall, these data demonstrate that NI NPCs can be successfully used in phenotypic 
compound screenings with the aim of developing personalized drug discovery approaches for 
neurological mtDNA diseases (Fig. S7G).  
 
Discussion 
Technical and methodological limitations have impeded the development of models 
for the development of individualized approaches to diseases caused by mutations in 
mitochondrial genes. Here we describe an innovative system based on iPSC-derived NPCs 
that can be used both to discover the cellular mechanisms that these mutations disrupt and 
develop novel treatments based on screens or other methods.  
We show that NPCs undergo functional mitochondrial maturation and develop 
oxidative metabolism in a way that resembles normal neuronal development. During this 
process, the cells preserve the patient-specific nuclear and mitochondrial matched genotypes. 
This is crucial in the study of mtDNA disorders, given that the nuclear background is thought 
to play a modulatory role in in these diseases (Benit et al., 2010; D'Aurelio et al., 2010), as 
illustrated by the phenotypic differences associated with the same homoplasmic MT-ATP6 
mutation (Aure et al., 2013; Pitceathly et al., 2012). Hence, NPCs should be useful in 
dissecting the specific vulnerability of the nervous system to mtDNA diseases (Abramov et 
al., 2010; Carelli and Chan, 2014).  
The approach described here for a homoplasmic mtDNA mutation should be equally 
applicable to heteroplasmic mutations. In fact, iPSC-derived NPCs retained the entire mtDNA 
profile of the initial fibroblasts, including even the hypervariable D-loop region. Studies have 
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indicated that the induction to iPSCs may be associated with heteroplasmic mtDNA 
alterations (Folmes et al., 2013; Hamalainen et al., 2013; Perales-Clemente et al., 2016; 
Prigione et al., 2011b). These variations appear to derive from the clonal origin of the iPSCs, 
because they also occur in clonally-expanded fibroblasts (Kang et al., 2016; Ma et al., 2015). 
This means that the mtDNA sequence profile of patient-derived iPSC lines must be 
thoroughly assessed to ensure that the cells are suitable for use in drug discovery or other 
types of treatments.  
Our finding that the MT-ATP6 mutation disrupted mitochondrial calcium homeostasis 
specifically in NPCs but not in fibroblasts or cybrids may help explain the specificity of the 
defects it causes. Neuronal cells are particularly sensitive to changes in calcium handling 
(Neher and Sakaba, 2008), which is considered a major contributor to excitotoxic cell death 
(Orrenius et al., 2003). The occurrence of aberrantly reduced cytoplasmic calcium in 
NPC_ATP6 cells might also explain the beneficial effects observed when patients carrying 
the MT-ATP6 mutation are treated with acetazolamide (Aure et al., 2013). Acetazolamide 
activates calcium-activated potassium [KCa] plasma membrane channels, whose opening is 
hindered by reductions in the amount of cytosolic calcium (Sah and Faber, 2002). Our new 
data imply that targeting the MMP, which lies “upstream” of calcium dyshomeostasis, may be 
a useful strategy to address the neural impairment that develops through the mutation (Fig. 
7K). This fits with results from cellular and animal models, which showed that mild 
uncouplers can improve neural calcium homeostasis (Maragos and Korde, 2004).  
Further work is needed to dissect the mechanisms responsible for the disruption of 
mitochondrial calcium homeostasis in NPC_ATP6 cells. Mitochondrial hyperpolarization, 
which promotes the sequestration of calcium into mitochondria (Rizzuto et al., 2012), might 
be responsible for the reduced mitochondrial calcium release observed in the cytoplasm. 
Another possibility is an impairment in the regulation of mitochondrial calcium efflux 
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mechanisms such as the sodium calcium exchanger (NCX) or the permeability transition pore 
(PTP), which consists of dimers of ATP synthase (Giorgio et al., 2013) (Fig. 7K).  
We also carried out the first phenotypic small molecule screening in patient-derived 
NPCs, which led to our identification of the PDE5 inhibitor avanafil as a potential therapeutic 
agent for use in MT-ATP6-related encephalopathies. PDE5 inhibitors increase the intracellular 
level of cyclic GMP (cGMP), which in turn activates [KCa] channels in both the plasma 
membrane and the inner mitochondrial membrane (Ahern et al., 2002; Szewczyk et al., 2006; 
Wang et al., 2008). The positive effects of avanafil on calcium homeostasis may thus be due 
to its effects on cellular polarization, which are similar to those of acetazolamide, and/or to its 
triggering of a slight mitochondrial depolarization, which would direct influence 
mitochondrial calcium homeostasis (Fig. 7K). Yet another possibility is that PDE5 inhibitors 
affect the opening of the PTP (Ascah et al., 2011). Further studies will be needed to clarify the 
mode by which avanafil and PDE5 inhibitors act in the context of MT-ATP6-associated neural 
impairment. Future work will also determine whether the compounds we have identified can 
also target mechanisms involved in other mitochondrial disorders. 
In conclusion, iPSC-derived NPCs appear well suited for use in drug screening 
strategies aimed at developing treatments for neurological mitochondrial disorders. Live cell-
based HCS permits the simultaneous evaluation of mitochondrial parameters beyond MMP 
(Iannetti et al., 2016), and might allow compound screenings aimed simultaneously at 
multiple mitochondrial phenotypes. The employment of FDA-approved libraries could speed 
up the process of translation to clinical applications through drug repositioning (Ashburn and 
Thor, 2004). We believe that creating disease-relevant in vitro model systems such as the one 
described here may represent an essential step toward the identification of effective therapies 
for mtDNA diseases and other conditions that cannot yet be treated. 
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Figure legends 
Figure 1. Generation of NI NPCs. (A) Upper panel, spiked morphology of NI NPCs and 
expression of NPC markers PAX6, SOX2, NESTIN, DACH1, and HES5. Lower panel, 
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neurospheres from NI NPCs and differentiated neurons (TUJ1-positive), including 
dopaminergic (TH-positive) and GABAergic neurons (GABA-positive), and astrocytes 
(GFAP-positive). Scale bar: 100 µm. (B) Representative images of NI NPCs (line NI H1) 
showing cytosolic calcium before stimulation and at maximal peak Fluo-4 fluorescence 
after 1 mM glutamate (Glu) stimulus. Scale bar: 50 µm. (C-D) Cytosolic calcium monitored 
in PSCs and NI NPCs following voltage-mediated (30 mM KCl) and receptor-mediated (1 
mM glutamate, Glu) stimuli. Time-point zero corresponds to stimuli administration. The 
profiles represent the average of PSCs (H1, H9, TFBJ) and corresponding NI NPCs (three 
biological replicates each). (E) Calcium responses were quantified by determining the area 
under the curve (AUC) of Fluo-4 fluorescence profiles. (F) Patch clamp recordings in NI 
NPCs and neurons and the effect of 100 nM tetrodotoxin (TTX) (shown here for line NI H1). 
(G) Membrane resistance (RN) and membrane potential (-Vm) during the course of 
differentiation (from NI H1 and NI TFBJ). Populations were separated in “none” (n=21 out of 
three biological replicates), “single” (n=13), and “repetitive” (n=6) action potential firing 
cells. (H) Principal component analysis (PCA) showing the transcriptomic clustering of 
fibroblasts (BJ, HFF1), hESCs (H1, H9), iPSCs (TFBJ, TDBJ5, TDHFF1), NI NPCs (NI H1, 
NI H9, NI TDBJ5, NI TFBJ), rNPCs, and eNPCs. Probe-sets were filtered for at least one 
present call and with an IQR> 25th percentile. (I) Mapping of the transcriptomic data of NI 
NPCs, eNPCs and rNPCs onto the Allen Human Brain Atlas. Color key displays the range of 
pairwise ranked correlation between analyzed sample matrix. Columns designate different 
time periods in the pre- and postnatal phase (wpc: week post-conception) and rows specify 
brain areas (AMY: amygdala, FC: frontal cortex, HIP: hippocampus, M1C: primary motor 
cortex). (J) Clustering performed using genes known to regulate energy metabolism. 
(K) qPCR expression analysis of two glycolytic regulators in fibroblasts (BJ, HFF1), NI 
NPCs (NI H1, NI H9, NI TDBJ5, NI TFBJ), rNPCs, eNPCs, and neurons (from NI H1 and NI 
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TFBJ). Values are presented as Log2 of the ratio between the expression values of GLUT3 or 
PDK1 over ACTB in relation to the undifferentiated PSC line H1.  
See also Figure S1, Figure S2, Table S1, and Video S1. 
 
Figure 2. Mitochondrial and metabolic reconfiguration upon neural induction. (A) 
Transmission electron microscopy (TEM) images showing the morphology of mitochondria 
within PSCs, NI NPCs, and differentiated neurons (shown are H1, NI H1, and neurons from 
NI H1). Scale bar: 500 nm. (B) Mitochondrial length quantified in PSCs (H1, H9, TDHFF1, 
TDBJ4, TDBJ5, TFBJ), NI NPCs (NI H1, NI H9, NI TDBJ5, NI TFBJ), and neurons (from 
NI TFBJ) (at least 60 mitochondria per cell line, out of at least 20 TEM images). (C) Oxygen 
consumption rate (OCR) profile using the Seahorse XF24 Analyzer for PSCs (H1, H9, TFBJ), 
fibroblasts (BJ, HFF1), NI NPCs (NI H1, NI H9, NI TFBJ), and neurons (from NI H1 and NI 
TFBJ) (at least two biological replicates per line, each with at least three technical replicates). 
Olig: 1 µM oligomycin; FCCP: 1 µM FCCP; R+AntA: 1 µM rotenone + 1 µM antimycin A. 
(D) Extracellular acidification rate (ECAR) profile, reflecting glycolytic activity, measured in 
parallel to OCR. (E-G) Spare respiratory capacity (shown in relation to PSCs), basal 
glycolysis, and OCR/ECAR ratio were calculated from the Seahorse profiling. Statistics refer 
to PSCs. (H) Extracellular lactate content in PSCs (H1, H9, TFBJ), fibroblasts (BJ, HFF1), NI 
NPCs (NI H1, NI H9, NI TFBJ), and neurons (from NI H1 and NI TFBJ) (at least two 
biological replicates per line, each with at least seven technical replicates). (I) Cellular 
proliferation in 25 mM glucose (+ glucose) or in 10 mM galactose (- glucose + galactose) for 
PSCs (H1, TFBJ), NI NPCs (NI H1, NI H9, NI TFC1), fibroblasts (BJ, HFF1) (at least two 
biological replicates per line, each with at least three technical replicates) (error bars represent 
SD). In all panels, unless otherwise indicated, error bars represent SEM and p values were 
determined by unpaired two-tailed Student’s t-tests: *P≤0.05, **P≤0.01, ***P≤0.001. 
See also Figure S2. 
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Figure 3. Preservation of mtDNA during reprogramming and neural induction. (A) 
Number of variants identified with whole mtDNA sequencing in fibroblasts (black), PSCs 
(red), and NI NPCs (blue). (B) Location of mtDNA variants (green ovals) in BJ fibroblasts 
(black circle), BJ-derived iPSC line TDBJ5 (red circle), and TDBJ5-derived NI TDBJ5 (blue 
circle). (C) Preservation of the D310 tract heteroplasmy within the hypervariable region of the 
D-loop (mtDNA nt 57-372) in two hESCs and their related NI NPCs, in BJ fibroblasts, BJ-
derived retroviral-based (TDBJ4 and TDBJ5) and plasmid-based (TFBJ and TFBJ.2) iPSC 
lines, and their respective NI NPCs. (D) Two different long-range PCR sets used to detect 
mtDNA deletions within PSCs and related NI NPCs. 
See also Table S2. 
 
Figure 4. Generation of NPC_ATP6 harboring the mutation m.9185T>C. (A) NPC 
markers, SOX2, NESTIN and PAX6, and proliferation marker Ki-67 in NPC_ATP6. Scale 
bar: 100 µm. (B) Whole mtDNA Sanger sequencing shown for the area around the mutation 
m.9185T>C for patient A2 in fibroblasts, iPSCs, and NPCs. (C) RFLP analysis confirming 
homoplasmic m.9185T>C mutation as a single 120 bp fragment (in control cells the 
restriction enzyme generates a 90 bp and a 30 bp fragment); WT: wild-type plasmid; Mut: 
mutant plasmid. (D) ATP production in permeabilized NPC_Ctrl (NI H1, NI H9, NI TDBJ5, 
NI TFBJ, NI TFC1, NI TFLR), NPC_ATP6 (NI A1, NI A2, NI A3), Fib_Ctrl (F20, F30, 
EF10), Fib_ATP6 (A1, A2, A3), Cyb_Ctrl (TFSR, 143B+), and Cyb_ATP6 (F06, F07, F08) 
(at least three biological replicates each, see Fig. S5I). (E) ATP content in intact cells in 
NPC_Ctrl (NI H1, NI H9, NI TFBJ) and NPC_ATP6 (NI A1, NI A2, NI A3) under basal 
condition and after 4 hours starvation, in Fib_Ctrl (BJ, HFF1, CON1, LR, NFH2), in 
Fib_ATP6 (A1, A2, A3), in Cyb_Ctrl (TFSR, 143B+), and in Cyb_ATP6 (F06, F07, F08) (at 
least three biological replicates each, see Fig. S5J-K). (F) Resting plasma membrane potential 
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in NPC_Ctrl (NI H1) and NPC_ATP6 (NI A2, NI A3), each with at least four biological 
replicates. (G) Proliferation curves of NPC_Ctrl (NI H1, NI TFBJ, NI TFC1, NI LR), 
NPC_ATP6 (NI A1, NI A2, NI A3), Fib_Ctrl (BJ, HFF1, CON1, LR, NFH2), Fib_ATP6 (A1, 
A2, A3), Cyb_Ctrl (TFSR, 143B+), and Cyb_ATP6 (F06, F07, F08). Cells were kept in either 
standard medium containing 25 mM glucose (+ glucose) or in medium deprived of glucose 
containing 10 mM galactose (- glucose, + galactose) (at least two biological replicates each). 
Error bars represent SD. (H) MitoSox fluorescence slope in NPC_Ctrl (NI H1, NI H9, NI 
TFC1), NPC_ATP6 (NI A1, NI A2, NI A3), Fib_Ctrl (EF1, EF10, EF9, EG1, EM2, FHN409, 
FHN505, KB2), Fib_ATP6 (A1, A2, A3), Cyb_Ctrl (TFSR, 143B+, EF9R, VFR1), and 
Cyb_ATP6 (F06, F07, F08) (at least three biological replicates each). In all panels, unless 
otherwise indicated, error bars represent SEM and p values were determined by unpaired two-
tailed Student’s t-tests: *P≤0.05, **P≤0.01, ***P≤0.001. 
See also Figure S3, Figure S4, and Figure S5. 
 
Figure 5. Mitochondrial hyperpolarization in neural cells carrying the MT-ATP6 
mutation. (A) MMP quantification in permeabilized cells presented as the difference between 
state 4 respiration (induced by 1 µM oligomycin) and state 3 respiration (induced by 1 mM 
ADP) (see Fig. S6A-C). At least three biological replicates per line: NPC_Ctrl (NI H1, NI H9, 
NI TFBJ, NI TFC1), NPC_ATP6 (NI A1, NI A2, NI A3), Fib_Ctrl (F20, F30, EF10), 
Fib_ATP6 (A1, A2, A3), Cyb_Ctrl (TFSR, 143B+), and Cyb_ATP6 (F06, F07, F08) (see Fig. 
S5L). (B) Imaging-based assessment of MMP in intact cells in NPC_Ctrl (NI H1, NI H9, NI 
TFBJ, NI TDBJ5, NI O3, NI O6, NI TFC2, NI TDHFF1), NPC_ATP6 (NI A1, NI A2, NI 
A3), Fib_Ctrl (BJ, HFF1, NFH2, Con1, LR), Fib_ATP6 (A1, A2, A3), Cyb_Ctrl (TFSR, 
143B+), and Cyb_ATP6 (F06, F07, F08) (at least three biological replicates each, see Fig. 
S5M). MMP was calculated by subtracting from the signal of untreated samples the signal 
obtained after treatment for 30 min with FCCP + antimycin A (both 1 µM). (C) Imaging-
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based quantification of MMP in intact differentiated Neur_Ctrl (from NI H1, NI TFBJ, NI 
O6) and Neur_ATP6 (from NI A2 and NI A3) (two biological replicates each, see Fig. S6F). 
(D) High-content screening (HCS)-based quantification of TUJ1-positive cells in Neur_Ctrl 
(from NI H1, NI TFBJ, NI O6) and Neur_ATP6 (from NI A2 and NI A3) (n=3 for each line). 
(E) Mitochondrial length measured in Neur_Ctrl (from NI TFBJ) and Neur_ATP6 (from NI 
A3) (at least 60 mitochondria each, out of at least 20 TEM pictures). (F) Ultrastructure images 
of differentiated Neur_Ctrl (from NI TFBJ) and from Neur_ATP6 (from NI A2 and NI A3). 
Scale bar: 2 µm. In all panels, unless otherwise indicated, error bars represent SEM and p 
values were determined by unpaired two-tailed Student’s t-tests: *P≤0.05, **P≤0.01, 
***P≤0.001. 
See also Figure S5 and Figure S6. 
 
Figure 6. Altered calcium homeostasis in NPC_ATP6. (A) Hierarchical clustering based on 
genes regulating mitochondrial calcium homeostasis (see Fig. S6G) in Fib_Ctrl (BJ, HFF1), 
Fib_ATP6 (A1, A2, A3), PSC_Ctrl (H1, H9, TDHFF1, TDBJ5, TFBJ), PSC_ATP6 (TFA2, 
TDA2.3, TDA3.1), NPC_Ctrl (NI H1, NI H9, NI TDBJ5, NI TFBJ), and NPC_ATP6 (NI A2, 
NI A3). (B) Expression of three genes involved in mitochondrial calcium homeostasis. p 
values were determined by ANOVA followed by a Tukey post-hoc test between NPC_Ctrl 
and NPC_ATP6. (C) Global proteomics analyzed as pair-wise comparison between 
NPC_ATP6 (NI A1, NI A2, and NI A3) and NPC_Ctrl (here shown in comparison to NI 
TFBJ, similar results were observed with NI H1, NI H9, and NI TFC1). (D) Representative 
images of NPC_Ctrl (line NI TFBJ) and NPC_ATP6 (line NI A3) showing basal cytosolic 
calcium before stimulation (basal) and at maximal peak Fluo-4 fluorescence after 1 mM 
glutamate (Glu) stimulation. Scale bar: 50 µm. (E) Cytosolic calcium release by exposing 
permeabilized cells to increasing doses of calcium (a: 5 mM CaCl2, b: 10 mM CaCl2, b: 50 
mM CaCl2 in Tyrode’s solution). NPC_Ctrl (NI H1, NI TFBJ, NI TDBJ5, NI TFC2; each 
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with at least three biological replicates) were compared to NPC_ATP6 (NI A1, NI A2, NI A3; 
each with at least four biological replicates). (F) Calcium release from mitochondria in 
permeabilized cells following exposure to FCCP and antimycin A (both 1 µM). NPC_Ctrl (NI 
H1, NI TFBJ, NI TDBJ5, NI TFC2; each with at least three biological replicates) were 
compared to NPC_ATP6  (NI A1, NI A2, NI A3; each with at least four biological replicates). 
(G) Calcium release from the ER in permeabilized cells treated with 1 µM thapsigargin. 
NPC_Ctrl (NI H1, NI H9, NI TFBJ; each with at least two biological replicates) were 
compared to NPC_ATP6 (NI A2, NI A3; each with at least three biological replicates). (H-I) 
Calcium responses in permeabilized Cyb_Ctrl (TFSR, 143B+) and Cyb_ATP6 (F06, F07, 
F08) (at least three biological replicates each). In all panels, unless otherwise indicated, error 
bars represent SEM and p values were determined by unpaired two-tailed Student’s t-tests: 
*P≤0.05, **P≤0.01, ***P≤0.001. 
See also Figure S6, Table S1, and Video S2. 
 
Figure 7. Phenotypic HCS in NPC_ATP6. (A) HCS-based quantification of MMP in live 
intact cells, using Hoechst for cell determination, TMRE for MMP, and PicoGreen for 
normalization over mtDNA content. Cellomics ArrayScan was employed according to the 
“Compartmental Analysis” BioApplication. (B) Screening of 130 FDA-approved compounds 
(all 1 µM in 0.04% DMSO overnight). NPC_ATP6 (NI A2) treated overnight with 0.04% 
DMSO (dark orange) were used as baseline. Dashed lines refer to 2SD distance from the 
baseline. Shown here are the average values (two biological replicates, each with two 
technical duplicates per compound). (C) ATP production in permeabilized NPC_ATP6 (NI 
A1, NI A2, NI A3, two biological replicates each) exposed to either DMSO or 1 µM avanafil 
overnight (see Fig. S7G). (D) ATP content in intact cells in Neur_ATP6 (from NI A2 and NI 
A3) after overnight treatment with DMSO or 1 µM avanafil (see Fig. S7H). (E-F) 
Cytoplasmic calcium response upon increasing doses of calcium (a: 5 mM CaCl2, b: 10 mM 
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CaCl2, b: 50 mM CaCl2 in Tyrode’s solution) in DMSO-treated NPC_ATP6 (DMSO) (NI A1, 
NI A2, NI A3; each with at least four biological replicates) and NPC_ATP6 treated with 1 
µM avanafil overnight (Ava) (NI A1, NI A2, NI A3; each with at least three biological 
replicates). (G-H) Cytoplasmic calcium response upon FCCP and antimycin A (both 1 µM) 
stimulation in DMSO-treated NPC_ATP6 (NI A1, NI A2, NI A3; each with at least four 
biological replicates) and NPC_ATP6 treated with 1 µM avanafil overnight (NI A1, NI A2, 
NI A3; each with at least three biological replicates). (I-J) Cytoplasmic calcium response in 
permeabilized DMSO-treated Neur_ATP6 (from NI A2 and NI A3) and in the same neurons 
treated overnight with 1 µM avanafil (see Fig. S7I). (K) Left side: suggested mechanisms 
underlying the impaired mitochondrial calcium handling of NPC_ATP6 cells; right side: 
potential mode action of avanafil (see discussion for details). CV: Complex V (MT-ATP6 in 
orange); H: hydrogen ions (protons); ETC: electron transport chain (Complexes I-IV); MCU: 
mitochondrial calcium uniporter, NCX: sodium-calcium exchanger; PTP: permeability 
transition pore; cGMP: cyclic GMP. In all panels, error bars represent SEM and p values were 
determined by unpaired two-tailed Student’s t-tests: *P≤0.05, **P≤0.01, ***P≤0.001. 
See also Figure S7 and Table S3. 
 
STAR Methods  
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for reagents may be directed to, and will be fulfilled by, the 
Lead Contact Alessandro Prigione (alessandro.prigione@mdc-berlin.de). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Fibroblasts and cybrids 
All fibroblast and cybrid cultures were maintained in DMEM medium (Gibco) 
containing 10% fetal bovine serum (FBS, Gibco), MycoZap antibiotics (Lonza), non-essential 
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amino acids, Pen/Strep, and sodium pyruvate (all Gibco). The cultures were kept in a 
humidified atmosphere of 5% CO2 at 37 °C under atmospheric oxygen conditions.  
The patient fibroblasts A1, A2, and A3, all harboring homoplasmic levels of the 
mutation m.9185T>C in the MT-ATP6 gene, were previously characterized (Aure et al., 
2013). Control fibroblasts included BJ, HFF1 (both from ATCC), Con1, Con2 (both kindly 
obtained from Dr. Sarah Doss, Charité University), and LR (from Prof. Markus Schülke, 
Charité University). Ethical approval was obtained by local authorities to use patient 
fibroblasts for iPSC derivation (IRB code #EA2/131/13) and approval from the State Office 
of Health and Social Affairs Berlin (LaGeSo) was obtained for the generation of human 
iPSCs using retroviruses (347/92-25). 
Control cybrids and mutant cybrids carrying the m.9185T>C mutation were previously 
reported (Aure et al., 2013). The mutant cybrids represented three different clones derived 
from A1 fibroblasts.  
Information regarding all individuals and control and patient lines utilized in this study 
are reported in Table S5. 
 
Pluripotent stem cells (PSCs) 
hESC lines (H1 and H9) were purchased from WiCell and used according to the 
German law (personal license to A.P., #AZ: 3.04.02/0077-E01). 
Control iPSCs included lines previously generated via transduction (TD) of the four 
Yamanaka retroviral factors, here labeled as TDHFF1, TDBJ4, and TDBJ5, previously 
reported as iPS2 (Prigione et al., 2010) and iB4 and iB5 (Prigione et al., 2011a), respectively. 
The retrovirally derived OiPS6 control iPSC line was also previously reported (Prigione et al., 
2011b).  
All pluripotent stem cells (PSCs) were cultivated on mitotically-inactivated mouse 
embryonic fibroblasts (MEFs) grown on Matrigel (BD Bioscience)-coated plates, using KO-
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DMEM medium (Gibco) containing 20% knock-out serum replacement (KSR, Gibco), 
8 ng/μl bFGF (PeproTech), MycoZap antibiotics, non-essential amino acids, Pen/Strep, and 
sodium pyruvate. For DNA and RNA isolation, PSCs were grown under feeder-free 
conditions on Matrigel-coated plates using DMEM/F12 medium supplemented with N2, B27, 
0.05% BSA (all from Gibco), 8 ng/μl bFGF, and non-essential amino acids, Pen/Strep, and 
sodium pyruvate. All PSCs were kept in a humidified atmosphere of 5% CO2 at 37 °C in 5% 
oxygen conditions.  
 
rNPCs and eNPCs 
Rosette-based NPCs (rNPCs) derived from the hESC line H9 were purchased from 
Aruna (hNP1, Aruna Biomedicals). Brain-derived ex vivo adult human NPCs (eNPCs) were 
bought from Lonza (Normal Human Neural Progenitor Cells, NHNP). All NPC cultures were 
kept in a humidified atmosphere of 5% CO2 at 37 °C under atmospheric oxygen conditions.  
 
METHOD DETAILS 
Derivation of iPSCs 
Control or patient fibroblasts were transduced with four transgene-encoding (OCT4, 
SOX2, KLF4, and c-MYC) retroviruses to generate transduction (TD)-iPSCs. Alternatively, 
they were transfected with episomal plasmids (containing the same four factors plus NANOG, 
LIN28, and SVLT) using Amaxa Cell Line Nucleofector Kit R (Lonza) to generate 
transfection (TF)-iPSCs. Transfection of episomal plasmids (Yu et al., 2011) was conducted 
using Amaxa Cell Line Nucleofector Kit R (Lonza), as previously described (Prigione et al., 
2014). Pluripotency of the generated lines was confirmed following previously published 
procedures (Prigione et al., 2010) using both in vitro embryoid bodies (EB)-based 
differentiation and teratoma formation (performed by EPO-GmbH). The karyotype was 
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assessed by chromosomal analysis after GTG-banding performed at the Human Genetic 
Center of Berlin, Germany. 
 
Generation of NI NPCs 
We obtained neural induction (NI) NPCs following on a previous report (Li et al., 
2011) with slight modifications. Briefly, 70% confluent PSCs were split and plated onto 
feeder-free Matrigel-coated dishes in DMEM/F12 medium. After 24 h, conditions were 
switched to NI-E medium (Neurobasal:DMEM/F12 [1:1], N2 [1x], B27 [1x], hLIF [10 
ng/ml], CHIR99021 [4 µM, Cayman Chemical], SB431542 [3 µM, SelleckChem], Compound 
E [0.1 µM, Calbiochem], BSA [0.05%], Pen/Strep, and L-glutamine). Medium was changed 
every other day. After one week, the cells were split as single cells using Accutase (Life 
Technologies) and further cultured in NI medium (Neurobasal:DMEM/F12 [1:1], N2 [1x], 
B27 [1x], hLIF [10 ng/ml], CHIR99021 [3 µM], SB431542 [2 µM], BSA [0.05%], Pen/Strep, 
MycoZap antibiotics, and L-glutamine). NI NPCs were then maintained in NI medium with 
change every other day. NI NPCs were split at ratios of 1:2 to 1:5 using a cell spatula when 
confluency reached 80-100%.  
 
Neuronal and astrocyte differentiation  
For neuronal differentiation, NI NPCs were plated at different densities (1-3 x106 per 
well) onto surfaces coated with Matrigel, poly-L-ornithine [20 μg/ml], and laminin [5 μg/ml] 
(both Sigma-Aldrich). For GABAergic neuronal differentiation, NI NPCs were plated on 
Matrigel, poly-L-ornithine [30 μg/ml], and laminin [5 μg/ml] in GA medium (DMEM/F12, 
N2 [1x], L-glutamine, Pen/Strep) containing BDNF [20 ng/ml] and SAG [200 nM] (Enzo Life 
Sciences). After four to five weeks, neuronal-like cells were cultured in GA medium with 
BDNF [20 ng/ml], IGF [10 ng/ml], and db-cAMP [300 ng/ml]. The maturation phase was 
extended for several weeks to allow electrophysiological measurements. Generation of 
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dopaminergic neurons was performed according to a previously published protocol (Reinhardt 
et al., 2013). NPCs grown on Matrigel were induced to differentiate for 8 days using a 
medium containing Neurobasal:DMEM/F12 [1:1], N2 [1x], B27 [1x], purmorphamine [1 
µM], vitamin C [200 µM], and FGF8 [100 ng/ml] and for 2 additional days using a medium 
containing Neurobasal:DMEM/F12 [1:1], N2 [1x], B27 [1x], purmorphamine [500 nM], and 
vitamin C [200 µM]. Cells were then split using Accutase at 1:3 ratios and plated onto 
matrigel-coated dishes. Conditions were switched to the maturation medium containing 
Neurobasal:DMEM/F12 [1:1], N2 [1x], B27 [1x], vitamin C [200 µM], db-cAMP [500 µM], 
BDNF [10 ng/ml], GDNF [10 ng/ml], and TGFbeta3 [1 ng/ml]. Differentiating neurons were 
kept in these conditions and the medium was changed every other day.  
To assess the efficiency of neuronal differentiation from control and patient NPCs, 
high-content screening (HCS)-based quantification of TUJ1-positive cells was performed. 
Briefly, NPCs were differentiated into dopaminergic neurons and plated on Matrigel-coated 
96-well plates. Cells were grown for 4 weeks (see culture conditions above) and then fixed 
and stained with TUJ1 antibody and counter-stained with Hoechst (see below for details on 
staining method). TUJ1-postive cells were counted using the “Neuronal profiling” 
BioApplication protocol of the HCS microscopy Cellomics ArrayScan (XTI Infinity High 
Content Platform, Life Technologies).  
The differentiation of NI NPCs into astrocytes was promoted by a standardized 
protocol (Krencik and Zhang, 2011) with slight modifications. In brief, NPCs were cultured 
as neurospheres in uncoated flasks with NI medium for 3 months during which progenitor 
clusters switched from neurogenic neurospheres to gliogenic astrospheres. To maintain their 
size during their expansion, spheres were regularly triturated with a flame-polished Pasteur 
pipette with smoothened edges and a 0.2-0.5 mm aperture diameter. After 3 months, spheres 
were dissociated to single cells with enzymatic digestion using Accutase (Life Technologies), 
transferred to new flasks at a concentration of at least 100,000 cells/ml and allowed to form 
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new clusters. This process was repeated for a further 30 days. For maturation, dissociated 
single cells were plated onto acid-etched, poly-L-ornithine - (40 µg/ml) and laminin-coated 
(40 µg/ml) coverslips at a density of 10,000 cells/cm2 for 7 days. For this final stage, hLIF, 
CHIR99021 and SB431542 in NI medium were replaced by rhCNTF (10 ng/ml, PeproTech). 
 
Calcium imaging 
Calcium studies were carried out by plating cells on glass bottom microwell dishes 
(MatTek) and incubating them in Tyrode’s solution (in mM: 129 NaCl, 5 KCl, 2 CaCl2, 1 
MgCl2, 25 HEPES, 30 Glucose, pH 7.4) supplemented with 5 μM Fluo-4 (Life Technologies) 
and 0.02% Pluronic F-127 (Sigma) for 45 min at RT and 5% CO2 in the dark. Fluorescence 
microscopy was performed using a Zeiss LSM780 confocal microscope system with a 20x 
objective, using time-series frames with an interval of 2 sec. After baseline interval, stimuli 
diluted in Tyrode’s solution were added, including high KCl (30 mM), L-glutamate (1 mM), 
FCCP and antimycin A (both 1µM), or thapsigargin (1 µM). Alternatively, increasing doses 
of calcium (5 mM, 10 mM, 50 mM CaCl2) were added in calcium-free Tyrode’s solution 
(Gandhi et al., 2009). Preincubation with digitonin (0.2 mM) was included for the last three 
stimuli. For each biological replicate, 10-20 cells were measured. Traces in the graphs 
represent the normalized average fluorescence intensity change over time. For quantification, 
the area under the curve (AUC) of the whole Fluo-4 fluorescence peak area was determined 
using GraphPad Prism.  
 
Whole mtDNA sequence analysis 
Total genomic DNA was isolated from cultured cells with the FlexiGene DNA kit 
(Qiagen). Two overlapping fragments, long 9,932 bp and 9,506 bp, were generated using the 
Expand Long Template PCR System (Roche). Fragments were separated by electrophoresis 
on 0.7% agarose gels. Both long fragments were also sequenced using the BigDye v1.3 
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protocol (Life Technologies) on an ABI3500 genetic analyzer (Applied Biosystems) using 
oligonucleotides placed at ≈400 bp intervals. Nested sequences were quality tested and 
aligned at the Cambridge reference sequence using the Geneious v6.0.5 software 
(Biomatters). Positions that deviated from the reference were annotated by the software and 
visually inspected.  
 
Global transcriptomics 
 Total RNA was isolated using the Qiagen isolation kit (Qiagen) and quality-checked 
by Nanodrop analysis (Nanodrop Technologies, Wilmington, DE, USA). Biotin-labeled 
cRNA samples were produced and hybridized onto Illumina human-12 BeadChips (Illumina, 
San Diego, CA, United States). Samples included HFF1, BJ, A1, A2, A3, H1, H9, TDHFF1 
(iPS2), TDBJ5 (iB5), TFBJ, TFA2, TDA2.3, TDA3.1, NI H1, NI H9, NI TDBJ5, NI TFBJ, 
NI A2, NI A3, eNPCs, rNPCs_Ar, and rNPCs_NI. Microarray analysis, PCA plot, and 
heatmaps were performed using the R/Bioconductor packages in the programming language R 
(version 3.1 or greater). Genes were considered significantly expressed with detection p 
values ≤ 0.01. Differential expression analysis was performed using the Illumina custom 
method, using differential p values ≤ 0.01, fold change ratio > 1.5. Pathway analysis was 
determined by mapping onto KEGG pathways using Database for Annotation, Visualization 
and Integrated Discovery (DAVID) (http://david.abcc.ncifcrf.gov). We fetched the 
significance level of normalized expression values corresponding to probe ID using lumi R’s 
(http://bioconductor.org/R package). Variance-stabilizing transformation (VST) was used to 
deal with sample replicates and robust spline normalization (RSN) for normalization. 
Significant samples (p-value < 0.05) were further transformed onto log2 scale and their IDs 
were annotated according to the IlluminaHumanv3.db Bioconductor annotation data package. 
Expression values of multiple probes for one gene were assigned by their median, resulting in 
analyzing 34,586 genes for each sample. The list of genes regulating energy metabolism was 
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based on the Human Glucose Metabolism PCR Array (SA Bioscience, 
http://www.sabiosciences.com), as previously described (Prigione et al., 2011a). 
Microarray raw data for NPCs from different studies were obtained from the National 
Center for Biotechnology Information Gene Expression Omnibus database under the series 
accession GSE25673 (Brennand et al., 2011), GSE28595 (Li et al., 2011), GSE40556 
(Reinhardt et al., 2013), GSE55107 (Hargus et al., 2014) and GSE57595 (Stein et al., 2014). 
Datasets were processed and normalized as above. In order to create a matrix of expression 
level for unique genes in each sample, the datasets were merged by their gene names 
representing median of their respective probes resulted in a total of 16,493 genes for 198 
samples. Differential expression between samples from various datasets was performed by 
correction of batch effect arising from two different platforms and by normalizing each data 
set to a sample of the same genotype in order to merge data sets for downstream analysis. The 
corrected batch effect was confirmed by Principal Component Analysis (PCA). Each gene 
value was further assigned as their relative abundance value, which corresponded to the 
expression value of the gene in each sample divided by its mean expression value across the 
samples. The resulting expression matrix was subjected to hierarchical clustering (Spearman 
correlation, average linkage) and p-value threshold. Fold change of differential expression 
between samples on log2 scale was analyzed using linear and Bayesian model algorithms 
from limma (http://bioconductor.org/R package) and pairwise differential. Heatmaps 
displaying Z-score were generated with matrix hierarchically clustered. Similar comparative 
analysis was performed on datasets of different stages of brain development. Brain data was 
downloaded from Allen Brain Atlas data portal (http://human.brain-map.org/static/download) 
and a matrix of 17,282 genes and 508 samples was created for further analysis as mentioned 
above.  
 
Global proteomics 
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NPC_Ctrl (lines NI H1, HI H9, NI TFBJ, NI TFC1) and NPC_ATP6 (lines NI A1, NI 
A2, NI A3) were harvested and lysed under denaturing conditions in a buffer containing 4% 
SDS, 0.1 M DTT, 0.1 M Tris pH 8.0. Lysates were sonicated and boiled at 95°C, each for 5 
min. Proteins were precipitated in 100% acetone ON at -20°C and re-dissolved in a buffer 
containing 6 M GdmCL, 10 mM TCEP, 40 mM CAA, 100 mM Tris pH 8.5. A dilution buffer 
(10% acetone, 25 mM Tris pH 8.5) in the ratio 1:10 (lysate:buffer) was added. 1% of the total 
lysates were finally digested by 1 µg trypsin at 37°C, ON. Peptides were acidified with a final 
concentration of 1% formic acid. 10% of the digest was directly used for LC-MS/MS 
analysis, the remaining 90% were further fractionated by strong cation exchange (SCX) 
chromatography with the following 5 SCX buffers: 2, 3, 4, 5 and buffer X, according to 
(Kulak et al., 2014). Dried fractions were dissolved in 5% acetone, 2% formic acid and 
subsequently injected for LC-MS/MS analysis. LC-MS/MS was carried out by nanoflow 
reverse phase liquid chromatography (Dionex Ultimate 3000, Thermo Scientific, Waltham, 
MA) coupled online to a Q-Exactive Plus Orbitrap mass spectrometer (Thermo Scientific, 
Waltham, MA). Briefly, the LC separation was performed using a PicoFrit analytical column 
(75 μm ID × 40 cm long, 15 µm Tip ID (New Objectives, Woburn, MA)) in-house packed 
with 2.1-µm C18 resin (Reprosil-AQ Pur, Dr. Maisch, Ammerbuch-Entringen, Germany) 
under controlled temperature of 50°C. Peptides were eluted using a non-linear gradient from 2 
to 40% solvent B over 180 min at a flow rate of 266 nL/min (solvent A: 99.9% H2O, 0.1% 
formic acid; solvent B: 79.9% acetonitrile, 20% H2O, 0.1% formic acid). 3kV were applied 
for nanoelectrospray generation. A cycle of one full FT scan mass spectrum (300−1750 m/z, 
resolution of 70 000 at m/z 200, AGC target 1e6) was followed by 12 data-dependent MS/MS 
scans (200-2000 m/z, resolution of 35 000, AGC target 5e5, isolation window 2 m/z) with 
normalized collision energy of 25 eV. Target ions already selected for MS/MS were 
dynamically excluded for 30 s. In addition, only peptide charge states between two to eight 
were allowed. The label-free software MaxLFQ (Cox et al., 2014), which is integrated into 
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MaxQuant (version 1.5.0.0) , was used for quantification (Cox and Mann, 2008) and searched 
against the human proteome database UniProtKB with 88.717 entries, released in 11/2014. A 
false discovery rate (FDR) of 0.01 for proteins and peptides and a minimum peptide length of 
7 amino acids were required. A maximum of two missed cleavages was allowed for the 
tryptic digest. Cysteine carbamidomethylation was set as fixed modification, while N-terminal 
acetylation and methionine oxidation were set as variable modifications.  
For comprehensive proteome data analysis, we applied gene set enrichment analysis 
(GSEA, v2.2.1) (Subramanian et al., 2005) in order to see if priori defined sets of proteins 
show statistically significant, concordant differences between patients and controls. The 
intensity of detected proteins of each data group was averaged and zero values were replaced 
by 2 prior to log2 transformation. We used GSEA standard settings, except the minimum size 
exclusion was set to 10 or 15 and C2 (collection of pathways) or C5 (1454 gene annotations) 
were used as gene set databases (http://software.broadinstitute.org/gsea/msigdb/index.jsp).  
 
PCR analysis 
For long-range mtDNA-PCR, products were generated with nested primers in order to 
prevent sequencing of the numerous nuclear pseudogenes of the mtDNA (Hazkani-Covo et 
al., 2010). Both long fragments were sequenced using the BigDye v1.3 protocol (Life 
Technologies) on an ABI3500 genetic analyzer (Applied Biosystems) using oligonucleotides 
placed at ≈400 bp intervals, as previously described (Detjen et al., 2007).  
Gene expression analysis was performed by quantitative real-time PCR (qPCR) using 
SYBR Green PCR Master Mix and the ViiA™ 7 Real-Time PCR System (Applied 
Biosystems). For each target gene, cDNA samples and negative controls were measured in 
triplicates using 384-Well Optical Reaction Plates (Applied Biosystems). Relative transcript 
levels of each gene were calculated based on the 2− ΔΔCT method. Data were normalized to 
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the housekeeping genes ACTB and GAPDH and are presented as mean LOG2 ratios in 
relation to control lines.  
For mtDNA copy number, the analysis was carried out with qPCR using LightCycler 
480 SYBR Green I Master Mix (Roche) with addition of 10 pM of each primer on a LC480 
Roche instrument (Roche) as follows: 95 °C for 10 min, 40 cycles (95 °C for 15 s, 60 °C or 
62 °C for 30 s, 72 °C for 30 s), 1 cycle (95 °C for 30 s, 60 °C for 30 s, heating to 95 °C and 
cooling to 37 °C). mtDNA was quantified as copies per µL by amplification of a fragment of 
the 12S mtDNA gene, with a standard curve obtained from serial dilutions of the linearized 
plasmid pGEM®-T Easy (Promega) containing the 12S mtDNA gene. Nuclear DNA was 
quantified as ng per µL by amplification of the 4401 – 4601 region of the single-copy 28S 
nuclear gene, with a standard curve obtained from serial dilutions of DNA from control 
fibroblasts. The mtDNA copy number was then calculated as copies per ng nuclear DNA. 
PCR-based restriction fragment length polymorphism (RFLP) analysis with the MnlI 
restriction enzyme of the m.9185T>C mutation was carried out according to a standardized 
protocol (Aure et al., 2013). Briefly, a 120 bp fragment of mtDNA was amplified from total 
DNA with Phusion polymerase (NEB) and MT-ATP6 primers. The product was digested with 
MnlI (NEB; 1 h at 37 °C) and separated in 2.5% agarose gels. Wild type (WT) mtDNA is 
cleaved by MnlI into two fragments of 90 and 30 bp. Similar DNA-based PCR approaches 
were employed to assess absence of episomal vectors using oriP primers and for 
fingerprinting of the generated iPSC lines using the primers D21S2055 and DS17S1290, as 
previously described (Prigione et al., 2010).  
The analysis of D-loop polymorphisms was performed as described before (Kirches et 
al., 2001). Briefly, PCR was performed with a FAM labeled forward-primer and a non-labeled 
reverse-primer. The products were digested with HaeIII and the fluorescent fragment sizes 
were determined with the ABI3500 Genetic Analyzer using the GeneMarker v1.51 software 
(SoftGenetics). Signals were transformed into curve diagrams, and the integral below the 
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curve was taken as the relative amount of the respective length fragment. mtDNA deletions 
was investigated using two different long-range PCR sets (Deschauer et al., 2004). All primer 
sequences are reported in Table S4.  
 
Immunostaining 
Cells were fixed with 4% paraformaldehyde (PFA, Science Services) for 20 min at RT 
and washed two times with PBS. For permeabilization, cells were incubated with blocking 
solution containing 10% FBS and 1% Triton X-100 (Sigma-Aldrich) in PBS with 0.05% 
Tween 20 (Sigma-Aldrich) (PBS-T) for 1 h at RT. Primary antibodies included NESTIN 
(Millipore, 1:200), PAX6 (BioLegend, 1:200), SOX2 (Santa Cruz, 1:100), TUJ-1 (Sigma-
Aldrich, 1:3000), OCT4 (Santa Cruz, 1:300),  LIN28 (ProteinTech Europe, 1:300), 
VIMENTIN (Sigma-Aldrich, 1:300), MAP2 (Synaptic System, 1:100), GFAP 
(DakoCytomation, 1:20), GABA (Calbiochem, 1:10000), Ki-67 (DakoCytomation, 1:50), 
NANOG (R&D Systems, 1:200), DACH1 (ProteinTech Europe, 1:100), Smooth Muscle 
Actin (SMA) (DakoCytomation, 1:200), SOX17 (R&D Systems, 1:50), HES5 (Santa Cruz, 
1:50), TH (Millipore, 1:300), and TRA1-81 and SSEA1/3/4 (from Hybridoma Bank, all 
1:200). Primary antibodies were diluted in blocking solution and incubated for at least 1 h at 
RT. Prior to and following the 1 h incubation period with the corresponding secondary 
antibody (Alexa Fluor, 1:300, Life Technologies), cells were washed once in PBS-T and two 
times in blocking solution, 5 min each. Counterstaining of nuclei was achieved by incubation 
with 100 ng/ml 4’,6-diamidino-2-phenylindole (DAPI, Vector Laboratories) in PBS for 1 h at 
RT. All images were acquired using the confocal microscope LSM510 Meta (Zeiss) in 
combination with the AxioVision V4.6.3.0 software (Zeiss) and further processed with Adobe 
Photoshop CS-6 (Adobe Systems).  
 
Cell proliferation 
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PSCs (H1, TFBJ, 8 replicates each) were seeded as single cells at a density of 10,000 
cells/well in black-wall, clear-bottom plates (Corning) (coated with Matrigel) in normal 
StemMACS™ iPS-Brew XF medium (Miltenyi Biotec GmbH, 130-104-368). 10 µM Rock 
inhibitor (Enzo, ALX-270-333-M005) was added 2 hours before splitting and also after 
seeding, to promote single-cell survival. Cells were allowed to attach and recover for 72 
hours, before changing medium to normal E8 medium (containing 25 mM glucose) or E8-
galactose medium (glucose-free, with 10 mM galactose). After the medium change one plate 
was fixed (day 0). Additional plates were fixed on the following three days at the same time 
every day. 
Other cells (patient and control fibroblasts, NI NPCs, and cybrids) were seeded at a 
density of 5,000, 20,000 and 40,000 cells/well in black-wall, clear-bottom plates (Corning) 
(coated with Matrigel for NPCs) in normal DMEM (containing 25 mM glucose) or DMEM-
galactose (glucose-free, with 10 mM galactose) for fibroblasts and cybrids and NI medium 
(containing 25 mM glucose) or NI-galactose (glucose-free, with 10 mM galactose) for NI 
NPCs. Cells were allowed to attach for one hour, before one plate was fixed (day 0). 
Additional plates were fixed on the following three days at the same time every day. 
For fixation, cells were washed with PBS, incubated for 20 min in 4% PFA and 8.1 
µM Hoechst, and washed again with PBS for final storage. The analysis was performed both 
using fluorescence reading with a Tecan plate reader (Infinite M200) and the count of 
Hoechst (33342, Invitrogen) -positive spots according to the “spot detector” function of the 
high-content screening (HCS) analyzer Cellomics ArrayScan (see below). All data were 
normalized to values obtained at day 0 to obtain a relative proliferation curve.  
 
Bioenergetic assessment 
Live assessment of cellular bioenergetics was performed using Seahorse XF24 
extracellular flux analyzer (Seahorse Bioscience), as described previously (Pfiffer and 
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Prigione, 2015). Briefly, 40,000 cells were plated into each Matrigel-coated well of the XF24 
well plates and incubated overnight at 37 °C with 5% CO2. Assays were initiated by 
removing the growth medium and replacing it with unbuffered media. The cells were 
incubated at 37 °C for 60 min to allow media temperature and pH to reach equilibrium before 
starting the simultaneous measurement of mitochondrial respiration (oxygen consumption 
rate, OCR) and anaerobic glycolysis (extracellular acidification rate, ECAR). After baseline 
records, four additions (all products at 1 µM and from Sigma) were performed to test 
mitochondrial respiration functions. First oligomycin, a complex V blocker, inhibited 
OXPHOS and tested respiration coupling to ATP synthesis. Two consecutive administrations 
of FCCP, a protonophore uncoupling agent, decreased the MMP, therefore increasing 
respiration rate, and enabled the quantification of the maximal respiration under maximal 
mitochondrial uncoupling. The last injection of rotenone, a complex I blocker, and antimycin 
A, a complex III blocker, caused complete inhibition of mitochondrial respiration, thereby 
allowing us to probe the non-respiratory oxygen consumption. Normalization to DNA content 
in each well of the plate was performed using the CyQUANT Kit (Molecular Probes). 
Cellular ATP content was determined with the luciferase-based ATPlite Luminescence 
Assay Kit (Perkin Elmer), according to the provider’s instructions (Prigione et al., 2010). 
Briefly, 7000 cells were seeded in 100 µl medium per well in a 96-well plate and 
subsequently lysed with 50 µl of a solution that at the same time inactivates the endogenous 
ATPases. Further addition of 50 µl substrate solution containing Luciferase and Luciferin 
allows quantification of luminescence occurring upon the reaction with ATP. The emitted 
light is proportional to the ATP concentration in the cells and was measured with a Tecan 
plate reader (Infinite M200). Every sample was measured at least in triplicate. Results are 
presented as picomoles of ATP per 1000 cells. 
Extracellular lactate amount was quantified using a Lactate Colorimetric/Fluorometric 
Assay Kit (BioVision). Briefly, cells were seeded in a 96-well plate at a density of 40,000 
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cells/well and incubated overnight. The next day, medium was replaced by unbuffered media 
and incubated for 3 h. Subsequently, the supernatants were collected and lactate measurement 
was performed according to the manufacturer’s instructions. Samples were prepared in 
triplicates and mixed 1:1 with a reaction mix containing enzymes and a lactate probe to 
proportionally produce fluorescence that could be measured with a Tecan plate reader 
(Infinite M200). Normalization by DNA content was accomplished using CyQUANT 
(Molecular Probes). Results were presented as picomoles of lactate per well per DNA content. 
 ATP production was carried out as previously described (Aure et al., 2013). Briefly, 
cells diluted in 1 mM EGTA, 3 mM EDTA, 5 mM K phosphate and 100 mM K MES pH 7.2 
were permeabilized with 20 µg digitonin per million cells. Protein concentration was 
measured before addition of 0.8 % fatty acid free bovine serum albumin. 100 000 cells were 
incubated with 10 mM pyruvate, 10 mM glutamate, 5 mM malate, 20 mM succinate, 50 µM 
Ap5A (an adenylate kinase inhibitor), and 1 mM ADP. ATP steady state was then measured 
at 4 minutes interval (T0 T4), followed by addition of 8 µM antimycin A and 1 µM 
oligomycin and again ATP steady state measurement at 4 minutes interval (T’0 T’4). The 
production of ATP was calculated as [(T4 - T0) - (T’4 – T’0)]/(4 x prot concentration) and 
expressed as nanomoles ATP produced per minute and mg proteins. 
 
Transmission electron microscopy (TEM) 
All cells were grown on coated Thermanox plastic coverslips (Nalge Nunc 
International) and fixed with 2.5% glutaraldehyde in 50 mM sodium cacodylate buffer (pH 
7,4) supplemented with 50 mM sodium chloride for at least 30 min at RT. Specimens were 
washed in the same buffer and post-fixed for 1.5 h in 0.5% osmium tetroxide at RT, followed 
by 0.1% tannic acid for 30 min and 2% uranyl acetate for 1,5 h. Samples were dehydrated in a 
graded series of ethanol, embedded in Spurr’s resin (Low Viscosity Spurr Kit, Ted Pella, Inc) 
and polymerised at 60 °C. Ultra-thin sections (70 nm) were prepared using an ultra-
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microtome (Reichert Ultracut E, Leica) and mounted on copper TEM grids from. Sections 
were counter stained with uranyl acetate and lead citrate. Micrographs were recorded at 
varying nominal magnifications using a Philips CM100 microscope operated at 100 kV, 
which was equipped with a 1k F114 Fastscan CCD camera (TVIPS) or a Tecnai Spirit 
microscope operated at 120 kV, which was equipped with a 2k Eagle CCD camera (FEI). For 
ultrastructural analysis, areas covering entire neuronal cells were imaged automatically on the 
Tecnai Spirit microscope using the MSI-Raster application within the Leginon system. 
Regions of interest (up to 50x50 µm2) were selected at low magnification (560x) and 
successively imaged at 4400x and 15000x magnification applying a defocus of -100 µm and -
4 µm, respectively. Obtained micrographs were then montaged to single images using 
TrakEM2 within the FIJI software package (Cardona et al., 2012).  
 
MMP quantification in permeabilized cells 
Cells were diluted in 1 mM EGTA, 3 mM EDTA, 5 mM K phosphate and 100 mM K 
MES pH 7.2 and permeabilized with 20 µg digitonin per million cells. Addition of 0.8 % fatty 
acid free bovine serum albumin and 200 nM rhodamine 123 was followed by distribution of 
the cells in four bioenergetic conditions: resting basal state= 10 mM glutamate and 5 mM 
malate, state 3 respiration= 10 mM glutamate, 5 mM malate and 1 mM ADP, state 4 
respiration= 10 mM glutamate, 5 mM malate, 1 mM ADP and 1 µM oligomycin, and 
complete depolarization= 10 mM glutamate, 5 mM malate, 1 mM ADP, 1 µM oligomycin, 8 
µM antimycin A and 10 µM CCCP (carbonyl cyanide m-chlorophenyl hydrazone, a 
protonophore dissipating the inner membrane potential). Fluorescence signal was read on an 
Accuri C6 flow cytometer after gating the cell population based on forward and size scatters. 
Mitochondrial membrane potential was then calculated using the Nernst equation and 1% as 
the volume occupied by mitochondria in the volume of medium illuminated by the laser 
beam.  
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Imaging-based MMP assessment in intact cells 
Cellomics ArrayScan (XTI Infinity High Content Platform, Life Technologies) was 
used for automated fluorescence microscopy analysis of MMP. One day prior to the assay, 
cells were collected by Accutase isolation and seeded on a black-wall, clear-bottom plate 
coated with Matrigel at a density of 40,000 or 80,000 cells/well on 96-well plates (Falcon) 
and incubated in NI medium overnight at 37 °C, 5% CO2. On the day of the assay, live cells 
were stained for 30 min with 10 nM TMRE (Molecular Probes, Life Technologies) for MMP 
and 3 µl/ml PicoGreen (Quant-iT™ PicoGreen dsDNA Assay Kit, Life Technologies) for 
mtDNA content normalization. Control staining was performed in parallel in cells exposed to 
1 µM FCCP and 1 µM antimycin A (both from Sigma) to cause complete mitochondrial 
depolarization. All cells were then washed with PBS and stained with 1:10,000 Hoechst 
(33342, Invitrogen) diluted in phenol red-free-DMEM for 10 min at RT (or 37 °C). After 
additional PBS washes, cells were kept in phenol red-free-DMEM for the duration of the 
assay. Images and analysis of Hoechst, TMRE and PicoGreen stainings were conducted with 
the Cellomics ArrayScan microscope according to the “Compartmental Analysis” 
BioApplication. The MMP values were extrapolated from the Cellomics measurements using 
the formula: TMRE (spot intensity * spot count) / PicoGreen (spot intensity * spot count). 
The results were calculated for each sample by subtracting the MMP value of the sample 
treated with FCCP and antimycin A from the MMP value of the sample under untreated 
conditions. The data are then presented in the paper as (TMRE / PicoGreen, a.u.). 
 
High-content screening (HCS) 
For the proof-of-principle compound screening, 130 compounds were taken from a 
library of 700 FDA-approved drugs (Selleckchem- z65122) (Table S3). The potentiometric 
TMRE probe signal was normalized to the signal of the fluorescent DNA dye PicoGreen. NI 
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medium (see supplemental text for details) was supplemented with HEPES (Thermo Fisher) 
to allow the stable quantification of live MMP in a position-independent manner within 384-
well plates. Briefly, 15,000 cells/well were plated on 384-well plates (Falcon) the day before 
the screening and a final concentration of 1 µM of the compounds was added. The second 
day, the medium was removed and the cells were stained with 10 nM TMRE and 3 µl/ml of 
PicoGreen together with 1:50,000 Hoechst diluted in phenol red-free NI medium for 30 min at 
37 °C, 5% CO2. Control staining was performed in parallel with cells exposed to 1 µM FCCP 
and 1 µM antimycin A (both from Sigma) to induce complete mitochondrial depolarization. 
After one washing step with NI medium without supplements, cells were kept in phenol red-
free NI medium for the duration of the assay.  
Each compound was used at a concentration of 1 µM dissolved in 0.04% DMSO and 
tested in duplicate. The same screening was repeated twice and the values shown in Fig. 7C 
represent the average of all the replicates. In every HCS plate, the control line NI H1 was 
included to control for inter-plate variability. Compound-treated and DMSO-treated cells 
were left overnight in NI medium and assessed for live MMP using 10 nM TMRE and 3 µl/ml 
of PicoGreen together with 0.2 µg/ml Hoechst (Invitrogen) diluted in phenol red-free NI 
medium. Treatment with FCCP and antimycin A (both 1 µM, Sigma) was used as positive 
control. HCS was conducted with Cellomics ArrayScan microscope (Thermo Fisher) and 
analyzed according to the “Compartmental Analysis” BioApplication. 
 
Mitochondrial reactive oxygen species (ROS) production 
The rate of mitochondrial ROS production was measured using the mitochondria-
specific probe MitoSOX Red (Life Technologies). After incubation in normal or glucose-free 
medium for 4 h, cells were harvested in their culture medium, 5x105 cells were loaded with 5 
µM MitoSOX Red at 37 °C during 10 min and analyzed by flow cytometry at different time 
points during 20 min. After gating on cells, the median fluorescence intensity was calculated 
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for each time point and plotted as a function of time. The relative increase in fluorescence 
intensity per minute was used to eliminate the bias introduced by different dye accumulation 
due to MMP variation (Polster et al., 2014). 
 
Electrophysiology 
NPCs and neuronal cells were probed on coated coverslips. An EPC-7 amplifier and 
Patchmaster software (HEKA) were used for patch clamp recordings. Patch pipettes, made 
from borosilicate glass (Science Products, Hofheim, Germany), had resistances of 3-7 MΩ 
when filled with the intracellular solution containing (in mM): potassium gluconate (110), 
KCl (25), NaCl (5), CaCl2 (0.5), MgCl2 (1), EGTA (5) and HEPES (30). The standard 
extracellular solution (E1) (pH 7.4) contained (in mM): NaCl (140), KCl (5), MgCl2 (1), 
CaCl2 (2), HEPES-NaOH (10) and glucose (10). Series and input resistances were checked 
throughout the whole duration of each experiment by applying -5 mV-pulses in the voltage 
clamp mode at -50 mV.  
Resting membrane potential was determined in the current clamp mode at 0 pA. 
Action potential generation of NPCs and neurons was measured in the current clamp mode by 
applying a holding current of -5 to -30 pA, so that the membrane potential was -70 mV. 
Increasing current pulses (300 ms; 5 pA to 50 pA) were applied every 5 sec to evoke action 
potentials, if any. All patch clamp experiments were performed at room temperature (20–25 
°C). 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Data were expressed as mean and standard deviation (mean ± SD) or standard error of 
the mean (mean ± SEM) where normality of the distribution could be verified, or as median 
and quartiles (median [1st;4th quartiles]) otherwise. For all experiments, multiple technical 
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replicates and biological replicates were utilized. Detailed information regarding the number 
of replicates for each experiment can be found in the respective figure legend. 
Significance was assessed using parametric tests (Student's t-test, ANOVA) for 
normally-distributed data and non-parametric tests (Mann-Whitney U test, Kruskal-Wallis) 
when normal distribution could not be verified. Data were analyzed using GraphPad-Prism 
software (Prism 4.0, GraphPad Software, Inc.), Veusz (http://home.gna.org/veusz/), and 
Microsoft Excel (Microsoft). 
 
DATA AND SOFTWARE AVAILABILITY 
Our microarray results have been deposited in the GEO database (accession number 
GSE70071). 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository 
(Vizcaino et al., 2013) with the dataset identifier PXD004977. 







KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Mouse monoclonal anti-NESTIN, clone 10C2 Millipore MAB5326 
Rabbit polyclonal anti-PAX6  BioLegend 901301 
Goat polyclonal anti-SOX2 (Y-17) Santa Cruz sc-17320 
Mouse monoclonal anti-beta-tubulin (TUJ1), clone 2G10 Sigma-Aldrich T8578 
Mouse monoclonal anti-OCT-3/4 (C-10) Santa Cruz sc-5279 
Rabbit polyclonal anti-LIN28 ProteinTech Europe 11724 
TRA-1-81 Millipore MAB4381 
Mouse monoclonal anti-VIMENTIN, clone V9 Sigma-Aldrich V6630 
Guinea pig polyclonal anti-MAP2 Synaptic Systems 188 004 
Rabbit polyclonal anti-GABA Calbiochem PC213L 
Mouse polyclonal anti-GFAP DakoCytomation M076101 
Mouse monoclonal anti-Ki-67, clone Ki-67 DakoCytomation F 0788  
Goat polyclonal anti-NANOG R&D Systems AF1997 
Rabbit polyclonal anti-DACH1 ProteinTech Europe 10914-1-AP 
Mouse monoclonal anti-SMA, clone 1A4 DakoCytomation M0851 
Goat polyclonal anti-SOX17 R&D Systems AF1924 
Rabbit polyclonal anti-HES5 (M-104) Santa Cruz sc-25395 
Rabbit polyclonal anti-tyrosine hydroxylase Millipore AB152 
SSEA-4 Developmental 
Studies Hybridoma 
Bank (DSHB) 
MC-813-70 
 
SSEA-3 DSHB MC-631 
SSEA-1 DSHB MC-480 
Biological Samples 
Patient fibroblasts A1, A2, and A3 carrying homoplasmic 
levels of the mutation m.9185T>C in the MT-ATP6 gene 
Dr. Anne Lombès Aure et al., 2013 
hNP1 Human Neural Progenitor Cells (from WA09) Aruna Biomedicals hNP7013.1 
Brain-derived ex vivo adult human NPCs (eNPCs, 
Normal Human Neural Progenitor Cells, NHNP) 
Lonza PT-2599 
Human ESC line H1 WiCell Research 
Institute 
WA01 
Human ESC line H9 WiCell Research 
Institute 
WA09 
Mutant cybrids carrying homoplasmic levels of the 
mutation m.9185T>C in the MT-ATP6 gene 
Dr. Anne Lombès Aure et al., 2013 
Control lines: see Table S5   
Chemicals, Peptides, and Recombinant Proteins 
Matrigel Matrix BD Biosciences 356231 
hLIF Miltenyi Biotec 130-108-156 
CHIR99021 Cayman Chemical 13122 
SB431542 SelleckChem S1067 
Compound E Calbiochem 15579 
SAG Enzo Life Sciences ALX-270-426-M001 
Poly-L-ornithine Sigma-Aldrich P4957 
Laminin Sigma-Aldrich L2020 
Thapsigargin Sigma-Aldrich T9033 
Fluo-4 Life Technologies F14201 
Pluronic F-127  Sigma-Aldrich P2443 
TMRE Molecular Probes T669 
StemPro Accutase Life Technologies A1110501 
Recombinant human CNTF PeproTech 450-13 
Rock inhibitor Enzo Life Sciences ALX-270-333-M005 
FCCP Sigma-Aldrich C2920  
Antimycin A Sigma-Aldrich A8674 
Oligomycin  Sigma-Aldrich 75351 
Rotenone Sigma-Aldrich R8875 
N2  Life Technologies 17502048 
B27 Life Technologies 17504044 
bFGF PeproTech 100-18B 
BDNF Miltenyi Biotec 130-096-286 
db-cAMP Sigma-Aldrich D0260-100 
Purmorphamine Miltenyi Biotec 130-104-465 
Vitamin C Sigma-Aldrich A4403 
GDNF Miltenyi Biotec 130-098-449 
TGFbeta3 Miltenyi Biotec 130-094-007 
FGF8 R&D Systems 4745-F8-050 
BSA  Sigma-Aldrich A9576 
IGF R&D Systems 291-G1-200 
StemMACS iPS-Brew XF Miltenyi Biotec 130-104-368 
HEPES Sigma-Aldrich H4034 
MycoZap Plus-CL Lonza VZA-2012 
MitoSOX Red  Life Technologies M36008 
Rhodamine 123 Sigma-Aldrich R8004 
CCCP Sigma-Aldrich C2759 
HumanHT-12 v4 Expression BeadChips Illumina BD-103-0204 
Critical Commercial Assays 
Lactate Colorimetric/Fluorometric Assay Kit  BioVision K607-100 
Expand Long Template PCR System Roche 11 681 834 001 
RNA isolation RNeasy Mini Kit Qiagen 74106 
FlexiGene DNA Kit Qiagen 51206 
SYBR Green PCR Master Mix Applied Biosystems,  4309155 
LightCycler 480 SYBR Green I Master Mix Roche 04707516001 
CyQUANT Kit Molecular Probes C7026 
ATPlite Luminescence Assay Kit Perkin Elmer 6016941 
Quant-iT™ PicoGreen dsDNA Assay Kit  Life Technologies P7581 
FlexiGene DNA kit Qiagen 51206 
Seahorse XF Cell Mito Stress Test 
 
Seahorse Bioscience, 
Agilent 
103015-100 
Deposited Data 
Microarray results GEO database accession number 
GSE70071 
Mass spectrometry proteomics data ProteomeXchange 
Consortium via PRIDE 
partner repository 
(Vizcaino et al., 2013) 
dataset identifier 
PXD004977 
Recombinant DNA 
Episomal plasmids (OCT4, SOX2, NANOG, KLF4) Yu et al., 2011 Addgene  
pEP4 E02S EN2K 
Episomal plasmids (OCT4, SOX2, SV40LT, KLF4) Yu et al., 2011 Addgene  
pEP4 E02S ET2K 
Episomal plasmids (c-MYC, LIN28) Yu et al., 2011 Addgene  
pCEP4-M2L 
Plasmid pGEM®-T Easy Promega A3600 
Primers: see Table S4   
Software and Algorithms 
HCS BioApplications (Compartmental analysis, 
Neuronal profiling)  
Cellomics ArrayScan 
Life Technologies 
https://www.thermofi
sher.com/de/de/hom
e/brands/thermo-
scientific/cellomics.ht
ml 
Geneious v6.0.5 software Biomatters https://www.geneiou
s.com/ 
ViiA™ 7 Software Applied Biosystems https://www.thermofi
sher.com/de/de/hom
e/technical-
resources/software-
downloads/applied-
biosystems-viia-7-
real-time-pcr-
system.html 
GeneMarker v1.51 software SoftGenetics http://www.softgeneti
cs.com/GeneMarker.
php 
AxioVision V4.6.3.0 software Zeiss http://www.zeiss.de/
mikroskopie/downloa
ds/axiovision-
downloads.html 
TrakEM2 within the FIJI software package  Cardona et al., 2012 http://imagej.net/Tra
kEM2 
GraphPad Prism Windows 5.04 GraphPad Software, 
Inc. 
http://www.graphpad
.com 
Database for Annotation, Visualization and Integrated 
Discovery (DAVID) 
 http://david.abcc.ncif
crf.gov 
R/Bioconductor packages in the programming language 
R (version 3.1 or greater) 
 https://www.biocond
uctor.org/install/ 
Allen Brain Atlas  http://human.brain-
map.org/static/downl
oad 
MaxQuant (version 1.5.0.0) Cox and Mann, 2008 http://www.coxdocs.
org/doku.php?id=:m
axquant:start 
Gene set enrichment analysis (GSEA, v2.2.1) Subramanian et al., 
2005 
http://software.broadi
nstitute.org/gsea/ind
ex.jsp 
Other 
FDA-approved drugs (see Table S3) Selleckchem z65122 
 
